Literature DB >> 24038494

Outbreak response immunisation: The experience of Chad during recurrent measles epidemics in 2005 and 2010.

G Guerrier1, J Guerra, F Fermon, W B Talkibing, J Sekkenes, R F Grais.   

Abstract

Despite impressive gains in measles control globally, measles epidemics continue to occur in countries with insufficient vaccination coverage. WHO guidelines now recommend outbreak response immunisation (ORI) for controlling measles outbreaks in certain contexts. The objective of this study was to describe late and early response vaccination activities during two consecutive measles outbreaks that occurred in 2005 and 2010 in N'Djamena, Chad. Using Lot Quality Assurance Sampling, vaccination coverage was estimated to be low before the interventions. Following mass vaccination campaigns, measles cases declined. The timeliness and quality of ORI activities are crucial determinants of success. However, effective outbreak response should be accompanied by strong routine vaccination programmes to ensure sustainable high vaccination coverage.

Entities:  

Year:  2011        PMID: 24038494     DOI: 10.1016/j.inhe.2011.06.003

Source DB:  PubMed          Journal:  Int Health        ISSN: 1876-3405            Impact factor:   2.473


  2 in total

1.  Measles in Democratic Republic of Congo: an outbreak description from Katanga, 2010-2011.

Authors:  Lise Grout; Andrea Minetti; Northan Hurtado; Gwenola François; Florence Fermon; Anne Chatelain; Géza Harczi; Jean de Dieu Ilunga Ngoie; Alexandra N'Goran; Francisco J Luquero; Rebecca F Grais; Klaudia Porten
Journal:  BMC Infect Dis       Date:  2013-05-22       Impact factor: 3.090

2.  Local discrepancies in measles vaccination opportunities: results of population-based surveys in Sub-Saharan Africa.

Authors:  Lise Grout; Nolwenn Conan; Aitana Juan Giner; Northan Hurtado; Florence Fermon; Alexandra N'Goran; Emmanuel Grellety; Andrea Minetti; Klaudia Porten; Rebecca F Grais
Journal:  BMC Public Health       Date:  2014-02-21       Impact factor: 3.295

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.